RESCAP®

About Alloksys Life Sciences

Alloksys Life Sciences is a private, clinical-stage biotechnology company focused on transforming critical care medicine through its proprietary enzyme therapy, RESCAP® (rescuing alkaline phosphatase). The company's mission is to develop innovative treatments that expedite patient recovery, reduce severe complications like acute kidney injury, and lower mortality in intensive care settings. With positive interim Phase IIb results and ongoing Phase IIb/III trials, Alloksys is strategically targeting high-unmet-need indications in perioperative care, aiming to bring a first-in-class therapeutic to a rapidly growing critical care market.

About Alloksys Life Sciences

Alloksys Life Sciences is a private, clinical-stage biotechnology company focused on transforming critical care medicine through its proprietary enzyme therapy, RESCAP® (rescuing alkaline phosphatase). The company's mission is to develop innovative treatments that expedite patient recovery, reduce severe complications like acute kidney injury, and lower mortality in intensive care settings. With positive interim Phase IIb results and ongoing Phase IIb/III trials, Alloksys is strategically targeting high-unmet-need indications in perioperative care, aiming to bring a first-in-class therapeutic to a rapidly growing critical care market.

About Amrif

Amrif is a private, preclinical-stage biotech developing RESCAP, an oral alkaline phosphatase enzyme replacement therapy, targeting the root causes of multiple age-related diseases. The company's approach is grounded in scientific literature suggesting AP is crucial for gut barrier integrity, inflammation control, and longevity, with animal data showing lifespan extension. Amrif aims to translate these findings into a safe, natural, and broadly applicable therapeutic to improve healthspan. The company is led by a small team of seasoned experts and appears to be in the early stages of asset development and fundraising.

About Amrif

Amrif is a private, preclinical-stage biotech developing RESCAP, an oral alkaline phosphatase enzyme replacement therapy, targeting the root causes of multiple age-related diseases. The company's approach is grounded in scientific literature suggesting AP is crucial for gut barrier integrity, inflammation control, and longevity, with animal data showing lifespan extension. Amrif aims to translate these findings into a safe, natural, and broadly applicable therapeutic to improve healthspan. The company is led by a small team of seasoned experts and appears to be in the early stages of asset development and fundraising.

About Amrif

Amrif is a private, preclinical-stage biotech developing RESCAP, an oral alkaline phosphatase enzyme replacement therapy, targeting the root causes of multiple age-related diseases. The company's approach is grounded in scientific literature suggesting AP is crucial for gut barrier integrity, inflammation control, and longevity, with animal data showing lifespan extension. Amrif aims to translate these findings into a safe, natural, and broadly applicable therapeutic to improve healthspan. The company is led by a small team of seasoned experts and appears to be in the early stages of asset development and fundraising.

About Amrif

Amrif is a private, preclinical-stage biotech developing RESCAP, an oral alkaline phosphatase enzyme replacement therapy, targeting the root causes of multiple age-related diseases. The company's approach is grounded in scientific literature suggesting AP is crucial for gut barrier integrity, inflammation control, and longevity, with animal data showing lifespan extension. Amrif aims to translate these findings into a safe, natural, and broadly applicable therapeutic to improve healthspan. The company is led by a small team of seasoned experts and appears to be in the early stages of asset development and fundraising.

Therapeutic Areas